首页> 美国卫生研究院文献>Canadian Urological Association Journal >Stimulation of a non-functioning pituitary macroadenoma after administration of goserelin acetate for locally advanced prostate cancer causing a sustained elevation in PSA and testosterone
【2h】

Stimulation of a non-functioning pituitary macroadenoma after administration of goserelin acetate for locally advanced prostate cancer causing a sustained elevation in PSA and testosterone

机译:醋酸戈舍瑞林注射后局部无反应的垂体腺瘤刺激局部PSA和睾丸激素持续升高

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Long-acting luteinizing hormone-releasing hormone (LHRH) agonists, such as goserelin, have been used for locally advanced and metastatic prostate cancer for many years and are the main forms of androgen deprivation therapy (ADT). Acting on pituitary LHRH receptors, they initially stimulate a transient rise in serum follicle-stimulating hormone (FSH) and LH. Long-term administration of an LHRH analogue will eventually lead to down regulation of LHRH receptors, thus suppressing FSH and LH secretion. This in turn suppresses testosterone production hence achieving and maintaining androgen deprivation. This case highlights the potential anomaly of a sustained elevated serum testosterone in the context of newly diagnosed locally advanced prostate cancer with a co-existing pituitary macroadenoma after administration of LHRH analogues. Alternative methods of androgen deprivation must be considered in such patients.
机译:长效促黄体生成素释放激素(LHRH)激动剂(如goserelin)已用于局部晚期转移前列腺癌已有多年历史,并且是雄激素剥夺疗法(ADT)的主要形式。它们作用于垂体LHRH受体,最初会刺激血清促卵泡激素(FSH)和LH短暂升高。长期给予LHRH类似物最终将导致LHRH受体的下调,从而抑制FSH和LH分泌。这继而抑制了睾丸激素的产生,从而实现并维持了雄激素的缺乏。这种情况突出显示了在新诊断的局部晚期前列腺癌与LHRH类似物共存的垂体巨腺瘤同时存在的情况下,血清睾丸激素持续升高的潜在异常。在此类患者中,必须考虑替代雄激素的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号